Protocol Ledger

NCT06615050 · Phase III · RECRUITING

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplant

Interventional Phase III clinical trial protocol NCT06615050 sponsored by Incyte in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-02 Enrollment: 572 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06615050
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)572 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06615050
Protocol FieldVerified Registry Value
NCT IdentifierNCT06615050
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment572 participants (ESTIMATED)
Registered Start Date2025-04-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI